Stock comparison
Mettler-Toledo International
Xeris Biopharma Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
XERS
Xeris Biopharma Holdings
Market cap
$1.07B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MTD | XERS | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 49D | MTD |
| Benjamin Graham | 65B | 81D | XERS |
| Philip Fisher | 63C | 67C | XERS |
| Peter Lynch | 66B | 86C | XERS |
| Joel Greenblatt | 68B | 54C | MTD |
| Charlie Munger | 74B | 62D | MTD |
| Terry Smith | 70B | 56D | MTD |
Side-by-side metrics
| Metric | MTD | XERS |
|---|---|---|
| Market cap | $22.29B | $1.07B |
| P/E (TTM) | 25.3x | 92.7x |
| EV/EBIT | 21.6x | 42.3x |
| ROIC (TTM) | 36.09% | 12.84% |
| Gross margin | 57.79% | 81.59% |
| Net margin | 21.4% | 3.81% |
| Revenue CAGR 5y | 2.01% | 55.75% |
| EPS CAGR 5y | 6.12% | - |
| Debt / Equity | - | 2.9x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MTD leads on
- Debt / Equity-vs 2.9x+105%
- Market cap$22.29Bvs $1.07B+95%
- Net margin21.4%vs 3.81%+82%
- P/E (TTM)25.3xvs 92.7x+73%
XERS leads on
- Revenue CAGR 5y55.75%vs 2.01%+96%
- Gross margin81.59%vs 57.79%+29%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.